The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases
Autor: | Hester E. de Melker, Johannes A. Bogaards, R. Donken, Chris J.L.M. Meijer, Anita W M Suijkerbuijk, G. Ardine de Wit, Anna K. Lugnér |
---|---|
Přispěvatelé: | Pathology, CCA - Evaluation of Cancer Care |
Rok vydání: | 2016 |
Předmět: |
Pediatrics
medicine.medical_specialty economic evaluation Cost effectiveness Cost-Benefit Analysis Immunology review Cervical disease 03 medical and health sciences anogenital cancer 0302 clinical medicine Primary health Neoplasms Drug Discovery medicine Journal Article Humans 030212 general & internal medicine polyvalent vaccines Economics Pharmaceutical Papillomavirus Vaccines cost-effectiveness Papillomaviridae health care economics and organizations Pharmacology business.industry Head and neck cancer Papillomavirus Infections Vaccination virus diseases Hpv vaccination Human Papillomavirus medicine.disease Anogenital cancer 030220 oncology & carcinogenesis Economic evaluation Molecular Medicine head and neck cancer vaccination program business |
Zdroj: | Expert Review of Vaccines, 16(4), 361. Expert Reviews Ltd. Suijkerbuijk, A W M, Donken, R, Lugnér, A K, Wit, G A D, Meijer, C J L M, de Melker, H E & Bogaards, J A 2016, ' The whole story : a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases ', Expert Review of Vaccines, pp. 1-15 . https://doi.org/10.1080/14760584.2017.1256778 Expert Review of Vaccines, 1-15. Taylor and Francis Ltd. STARTPAGE=1;ENDPAGE=15;ISSN=1476-0584;TITLE=Expert Review of Vaccines |
ISSN: | 1744-8395 1476-0584 |
Popis: | INTRODUCTION: Many economic evaluations of HPV vaccination have been published, but most have focused on the prevention of cervical disease as a primary health outcome. The cost-effectiveness of vaccination is likely to be underestimated if not all HPV-associated diseases are taken into account. In this review, we assess the influence of non-cervical HPV-associated diseases on the incremental cost-effectiveness ratio (ICER) of preadolescent HPV vaccination. Areas covered: We systematically searched the literature and identified 18 studies that included non-cervical diseases in the estimates of cost-effectiveness of HPV-vaccination. When taking other HPV-related diseases into account compared to not including such other diseases, the mean ICERs were 2.85 times more favorable for girls only vaccination and 3.89 times for gender neutral vaccination. Expert commentary: Including non-cervical diseases in economic evaluations of HPV vaccination programs makes it more likely that the ICER falls beneath accepted cost-effectiveness thresholds and therefore increases the scope for gender neutral vaccination. |
Databáze: | OpenAIRE |
Externí odkaz: |